<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361424</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-PXT00864-03</org_study_id>
    <nct_id>NCT02361424</nct_id>
  </id_info>
  <brief_title>Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)</brief_title>
  <acronym>PLEODIAL-I</acronym>
  <official_title>First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharnext SA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ascopharm Groupe Novasco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharnext SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy on cognitive impairment and
      functioning of several doses of PXT00864 (new fixed combination of acamprosate and baclofen
      at low dose) in patients with mild Alzheimer Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the total score of the 11-item Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
    <description>Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater cognitive impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>throughout the 12-week study period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
    <description>Scores on the DSST range from 0-93 with lower scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the speed to perform the Zazzo's Cancellation Test</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the Zazzo's Cancellation Test</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the 15-second Isaacs Set Test</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the time score of the Trail Making Test - part A</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the time score of the Trail Making Test - part B</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the Free and Cued Selective Reminding Test (FCSRT)</measure>
    <time_frame>1 (baseline) and V4 (end of study, after 12 weeks of treatment)</time_frame>
    <description>FCSRT is a memory test administered according to the procedure described by Gröber and Buschke modified with 16 verbal items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the 4-item Instrumental Activities of Daily Living scale (IADL-PAQUID)</measure>
    <time_frame>V0 (train), V1 (baseline), and every 4 weeks (V2, V3 and V4)</time_frame>
    <description>The 4-item Instrumental Activities of Daily Living scale (IADL) concerns four routine daily functions (using transportation, managing finances, using the phone and managing medicines use). Scores on the IADL range from 4-15 with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the Clinical Dementia Rating (CDR) scale</measure>
    <time_frame>1 (baseline) and V4 (end of study, after 12 weeks of treatment)</time_frame>
    <description>The Sum of Boxes score of the CDR ranges from 0 to 18, with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the Apathy Inventory (AI) scale</measure>
    <time_frame>1 (baseline) and V4 (end of study, after 12 weeks of treatment)</time_frame>
    <description>Scores on the AI range from 0-12 with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in the cognitive Event Related Potential parameters (optional)</measure>
    <time_frame>V1 (baseline), and every 4 weeks (V2, V3 and V4)</time_frame>
    <description>Some cognitive Event Related Potentials (ERP) with auditory oddball paradigm are performed as an ancillary study.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>PXT00864 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 orange capsule containing 0.4 mg of acamprosate , and 1 white capsule containing 6 mg of baclofen These 2 capsules are taken orally b.i.d. during 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT00864 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 orange capsule containing 1 mg of acamprosate , and 1 white capsule containing 15 mg of baclofen .
These 2 capsules are taken orally b.i.d. during 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT00864 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 orange capsule containing 20 mg of acamprosate , and 1 white capsule containing 12 mg of baclofen .
These 2 capsules are taken orally b.i.d. during 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of PXT00864</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 orange capsule containing placebo of acamprosate , and 1 white capsule containing placebo of baclofen .
These 2 capsules are taken orally b.i.d. during 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT00864</intervention_name>
    <description>PXT00864 is a fixed-dose combination of baclofen and acamprosate</description>
    <arm_group_label>PXT00864 Dose 1</arm_group_label>
    <arm_group_label>PXT00864 Dose 2</arm_group_label>
    <arm_group_label>PXT00864 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo of PXT00864</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged ≥ 60 years.

          -  Patient with a diagnosis of probable AD

          -  Progressive decline in cognition for more than six months which story is documented in
             patient medical records

          -  A Mini-Mental State Examination (MMSE) score of 20-26

          -  With a minimum of educational background

          -  Naïve to anti-dementia treatment

          -  MRI assessment which corroborates the clinical diagnosis (hippocampal atrophy) and
             excludes other potential causes of dementia especially cerebrovascular lesions

          -  If available, Cerebral Spinal Fluid (CSF) classical biomarkers should be at levels
             which corroborate the clinical diagnosis

          -  Ambulatory patient living at home with a caregiver available and living in the same
             household or interacting with the patient daily and available if necessary to ensure
             administration of the investigational product

          -  Absence of major or severe depressive disease

          -  Patient with a willingness to participate in this study and who have signed an
             informed consent form

        Exclusion Criteria:

          -  Early onset of dementia, i.e. before 60 years old to avoid hereditary AD forms

          -  Significant neurological disease other than AD

          -  Major psychiatric disorder or syndrome (schizophrenia or bipolar disorder)

          -  Seizure disorders

          -  Other infectious, metabolic or systemic diseases affecting central nervous system

          -  Other active clinically significant illness

          -  Hospitalization or change of chronic concomitant medications one month prior to
             screening

          -  Patients with severe respiratory, hepatic or renal failure or with any other
             significantly potentially disabling abnormality detected during screening

          -  Known hypersensitivity to the tested treatment including active substance and
             excipients.

          -  Patients participating in another study and exposed to any investigational therapy
             within the 30 days prior to the entry in this study.

          -  Patient without medical care insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Orgogozo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Pellegrin, Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMRR</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PXT00864</keyword>
  <keyword>mild AD</keyword>
  <keyword>phase 2a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

